

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 700 854 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

13.09.2006 Bulletin 2006/37

(51) Int Cl.:

C07D 319/06^(2006.01)(21) Application number: **06010837.0**(22) Date of filing: **12.07.2001**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**(30) Priority: **19.07.2000 NL 1015744**(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:**01953373.6 / 1 317 440**(71) Applicant: **AstraZeneca UK Limited****London W1K 1LN (GB)**

(72) Inventors:

- **Kooistra, Jacob Hermanus Mattheus Hero**
5925 BA Venlo (NL)
- **Zeegers, Hubertus Josephus Marie**
5991 CT Baarlo (NL)
- **Mink, Daniel**
4700 Eupen (BE)
- **Mulders, Joannes Maria Cornelis Antonius**
6166 HC Geleen (NL)

Remarks:

This application was filed on 26-05-2006 as a
divisional application to the application mentioned
under INID code 62.

(54) **Process for the preparation of 2-(6-substituted-1,3-dioxane-4-yl) acetic acid derivatives**

(57) The invention relates to the preparation of 2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivatives of formula 1, where X stands for a leaving group, and R₁, R₂, and R₃ each independently stand for an alkyl group with 1-3 carbon atoms from 4-hydroxy-6-X-substituted-methyl-tetrahydropyran-2-one compounds, where X is as defined above, with the aid of an acetalization agent, in the presence of an acid catalyst.


The invention also relates to the novel compounds of formula 1 as well as salts and acids to be prepared from these, with the OR₃ group in formula 1 being replaced by an OY group, where X, R₁ and R₂ have the meanings defined above and where Y stands for an alkaline (earth) metal or a substituted or unsubstituted ammonium group or stands for hydrogen, and to the novel compounds of formula 2.

The products concerned are, after conversion into the t-butyl ester of 2-(6-hydroxymethyl-1,3-dioxane-4-yl)acetic acid, important as intermediary products in the preparation of statins.


EP 1 700 854 A1

Description

[0001] The invention relates to a process for the preparation of a 2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivative of formula 1




where X stands for a leaving group, and R_1 , R_2 and R_3 each independently stand for an alkyl group with 1-3 carbon atoms, starting from a compound of formula 2



where X is as defined above, use being made of a suitable acetalization agent, in the presence of an acid catalyst.

[0002] The invention also relates to the new compounds of formula 1, as well as salts and acids of formula 3 that can be obtained therefrom



where R_1 and R_2 have the above-mentioned meanings and where Y stands for an alkaline (earth) metal or a substituted or non-substituted ammonium group or stands for hydrogen.

[0003] Applicant has surprisingly found that the 2-(6-substituted 1,3-dioxane-4-yl)-acetic acid derivative can be obtained selectively and in a high yield from the corresponding compound of formula (2), it being possible to prepare these products, which are relatively little stable, under mild conditions. This is all the more interesting since this provides a simple route via the corresponding salt, the corresponding t-butyl ester, and the 2-hydroxymethyl-substituted compound as intermediates in the preparation of HMG-CoA reductase inhibitors. Optionally the conversion proceeds (depending on the reaction conditions chosen) via an intermediary salt or ester, with the ring in the compound according to formula (2) being opened.

[0004] An added advantage of the process according to the invention is that both the starting compounds of formula (2) and the products of formula 3 are found to be crystalline compounds. This is advantageous in obtaining products with a (chemically and stereochemically) high purity. This is important in particular in view of the intended pharmaceutical application. For the intended application in particular the (4R,6S)-2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivative is important. It can be prepared from the corresponding 6-substituted-2,4,6-trideoxy-D-erythrohexose. The invention, therefore, also relates to the starting compounds of formula 1, in particular where $X=Cl$, and to particles of such compounds. In particular more than 90 wt. % of the particles has a length/diameter ratio between 1:1.5 and 1:6, preferably between 1:2 and 1:4.4 and a length of the particles between 0.05 and 2 mm, in particular between 0.1 and 1 mm. The invention also relates to such particles. The compound of formula II gives clear crystalline particles with a sharp melting point of 73-74 °C. The products of formula 3 derived from the (4R,6S)-2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivative of formula 1 can according to the invention be prepared with an enantiomeric excess (e.e.) of more than 95%,

in particular more than 99.5%, and with a diastereomeric excess (d.e.) of more than 90%, in particular more than 99.5%.

[0005] Examples of suitable leaving groups X that can be applied in the process according to the invention are halogens, in particular Cl, Br or I; tosylate groups; mesylate groups; acyloxy groups, in particular acetoxy and benzoyloxy groups; an aryloxy-, in particular benzyloxy-, or a nitro-substituted benzene sulphonyl group. For practical reasons Cl is preferably chosen as leaving group.

[0006] The groups R_1 , R_2 and R_3 each separately stand for an alkyl group with 1-3 carbon atoms, preferably methyl or ethyl. In practice $R_1 = R_2 = R_3 = \text{methyl}$ is most preferred.

[0007] Examples of suitable acetalization agents that can be applied in the process according to the invention are dialkoxypropane compounds, with the alkoxy groups each preferably having 1-3 carbon atoms, for instance 2,2-dimethoxypropane or 2,2-diethoxypropane; alkoxypropene, with the alkoxy group preferably having 1-3 carbon atoms, for instance 2-methoxypropene or 2-ethoxypropene. Most preferred is 2,2-dimethoxypropane. This can optionally be formed in situ from acetone and methanol, preferably with water being removed.

[0008] As acid catalyst use can be made of the acid catalysts known for acetalization reactions, preferably non-nucleophilic strong acids, for example sulphonic acids, in particular p-toluene sulphonic acid, methane sulphonic acid of camphor sulphonic acid; inorganic acids with a non-nucleophilic anion, for example sulphuric acid, phosphoric acid; acid ion exchangers, for example DOWEX; or solid acids, for example the so-called heteropolyacids.


[0009] The acetalization can be carried out without using a separate solvent; if desired the reaction can also be carried out in an organic solvent. Examples of suitable organic solvents are ketones, in particular acetone, hydrocarbons, in particular aromatic hydrocarbons, for example toluene, chlorinated hydrocarbons, for example methylene chloride.

[0010] The temperature at which the acetalization reaction is carried out preferably lies between -20°C and 60°C , in particular between 0°C and 30°C . The acetalization reaction is preferably carried out under an inert atmosphere.

[0011] The molar ratio of acetalization agent to starting compound of formula (2) preferably lies between 1:1 and 20:1, in particular between 3:1 and 5:1. Using an organic solvent the molar ratio is in particular between 1:1 and 2:1.

[0012] The molar ratio of acid catalyst to starting compound of formula (2) preferably lies between 1:1 and 0.001:1, in particular between 0.01:1 and 0.05:1.

[0013] The resulting 2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivative can subsequently be hydrolyzed in the presence of a base and water to form the corresponding salt of formula 3



where Y stands for an alkaline metal, an alkaline earth metal, or a substituted or unsubstituted ammonium group, preferably Na, Ca or a tetraalkyl-ammonium compound. Optionally, the hydrolysis is followed by conversion to the acetic acid according to formula 3 with $Y=H$.

[0014] The hydrolysis of the compound of formula (3) is preferably carried out with at least 1 base equivalent, in particular 1-1.5 base equivalents, relative to the compound of formula (3). In principle a larger excess can be used, but in practice this usually does not offer any advantages.

[0015] The reaction is preferably carried out at a temperature between -20°C and 60°C , in particular between 0°C and 30°C .


[0016] The hydrolysis can for example be carried out in water, an organic solvent, for example an alcohol, in particular methanol or ethanol, an aromatic hydrocarbon, for example toluene, or a ketone, in particular acetone or methyl isobutyl ketone (MIBK), or a mixture of an organic solvent and water, optionally catalysed by a phase transfer catalyst (PTC) or addition of a cosolvent.

[0017] The hydrolysis can also be carried out enzymatically, the desired diastereomer optionally being hydrolyzed selectively.

[0018] Examples of enzymes that can suitably be used in the process according to the invention are enzymes with lipase or esterase activity, for example enzymes from *Pseudomonas*, in particular *Pseudomonas fluorescens*, *Pseudomonas fragi*; *Burkholderia*, for example *Burkholderia cepacia*; *Chromobacterium*, in particular *Chromobacterium viscosum*; *Bacillus*, in particular *Bacillus thermocatenulatus*, *Bacillus licheniformis*; *Alcaligenes*, in particular *Alcaligenes faecalis*; *Aspergillus*, in particular *Aspergillus niger*; *Candida*, in particular *Candida antarctica*, *Candida rugosa*, *Candida lipolytica*, *Candida cylindracea*; *Geotrichum*, in particular *Geotrichum candidum*; *Humicola*, in particular *Humicola lanuginosa*; *Penicillium*, in particular *Penicillium cyclopium*, *Penicillium roquefortii*, *Penicillium camembertii*; *Rhizomucor*, in particular *Rhizomucor javanicus*, *Rhizomucor miehei*; *Mucor*, in particular *Mucor javanicus*; *Rhizopus*, in particular


Rhizopus oryzae, *Rhizopus arhizus*, *Rhizopus delemar*, *Rhizopus niveus*, *Rhizopus japonicus*, *Rhizopus javanicus*; porcine pancreas lipase, wheat germ lipase, bovine pancreas lipase, pig liver esterase. Preferably, use is made of an enzyme from *Pseudomonas cepacia*, *Pseudomonas sp.*, *Burkholderia cepacia*, porcine pancreas, *Rhizomucor miehei*, *Humicola lanuginosa*, *Candida rugosa* or *Candida antarctica* or subtilisin. If an enantioselective enzyme is used, even further enantiomer enrichment is realized during the hydrolysis. Such enzymes can be obtained using commonly known technologies. Many enzymes are produced on a technical scale and are commercially available.

[0019] The salts (acids) obtained are novel. The invention therefore also relates to these products of formula 3



where X stands for a halogen, in particular Cl, Br or I, a tosylate or mesylate group, an acyloxy group with 3-10 carbon atoms, or a nitro-substituted benzene sulphonyl group and Y stands for H, an alkaline (earth) metal, or a substituted or unsubstituted ammonium group.

[0020] The resulting salt of formula 3 can subsequently be converted into the corresponding t-butyl ester (formula 1a with $R_3 = t\text{-butyl}$), in a way known per se.



[0021] In the process according to the invention the compound of formula (3) can for example be esterified to form the corresponding tert. butyl ester using the following methods, which in general are described in literature:

- reaction with isobutene and strong acid, for example paratoluene sulphonic acid (pTS), sulphuric acid or a strongly acidic ion exchanger (US-A-3325466);
- reaction via the acid chloride and t-butanol, under the influence of a base, for example triethylamine (Et_3N), dimethylamino pyridine (DMAP). The acid chloride can be prepared with the aid of for example SOCl_2 , POCl_3 , $(\text{COCl})_2$ and catalyzed by for example dimethyl formamide (DMF) (J. Org. Chem. 35 2429 (1970));
- reaction via the acid chloride with Li-t-butanolate (Org. Synth. 51 96 (1971));
- transesterification with t-butyl acetate under the influence of a strong acid (Z. Chem. 12(7) 264 (1972));
- reaction of the salt with t-butyl bromide, preferably in DMF, dimethyl acetamide (DMAA), 1-methyl-2-pyrrolidinone (NMP) and using a phase transfer catalyst (PTC) (Tetr. Let. 34 (46) 7409 (1993));
- reaction of the acid with t-butanol, 1,3-dicyclohexyl carbodiimide (DCC) and DMAP (Synth. Comm. 9, 542 (1979));
- reaction of the acid with t-butyl-trichloro acetamidate (Tetr. Let. 39, 1557 (1998));
- reaction of the salt with carboxyl diimidazole (CDI) and t-butanol;
- reaction of the acid with pivaloyl chloride and t-butanol under the influence of DMAP or N-methyl-morpholin (NMM) (Bull. Chem. Soc. Japan 52 (7) 1989 (1979));
- reaction of the salt with di-tert. butyl dicarbonate, DMAP and t-butanol (Synthesis 1063 (1994));
- reaction of the acid with cyanuric chloride and pyridine or triethylamine (Org Process R&D 3, 172 (1999); Heterocycles 31 11, 2055 (1990)).

[0022] The resulting t-butyl ester of 2-(6-substituted-1,3-dioxane-4-yl)acetic acid can subsequently be converted into the 2-(6-hydroxymethyl-1,3-dioxane-4-yl)acetic acid, for example as described in US-A-5594153 or in EP-A-1024139, in the presence of a tetraalkyl ammonium halogenide and/or a carboxylic acid in the salt, via conversion into a compound of formula 1a with $R_3 = t\text{-butyl}$ and X = an acyloxy, for example an acetoxy group. The acyloxy group can subsequently be converted via solvolysis, in a way otherwise generally known, to a hydroxyl group. The solvolysis can be performed using a base (Na_2CO_3 , K_2CO_3 , or sodium methanolate in methanol), optionally by simultaneous distillation of the methyl

acetate formed.

[0023] The t-butyl ester of 2-(6-hydroxymethyl-1,3-dioxane-4-yl)acetic acid is a desirable intermediate product in the preparation of various statins, for example ZD-4522, as described in Drugs of the future, (1999), 24(5), 511-513 by M. Watanabe et al., Bioorg. & Med. Chem. (1997), 5(2), 437-444. The invention therefore provides a novel, interesting route to these intermediate products and to the end products, in particular statins.

[0024] The starting compounds of formula 2 can for example be obtained as described in WO-A-96/31615.

[0025] The invention will be elucidated with reference to the following examples, without however being restricted by these.

Example I

Preparation of (4R,6S)-4-hydroxy-6-chloromethyl-tetrahydropyran-2-one

(Compound II; covered by formula 2)

[0026] At room temperature 2.1 ml bromine was added in 45 minutes to a mixture of 6.7 g (40 mmol) 6-chloro-2,4,6-trideoxy-D-erythro-hexose (compound I; prepared according to the method described in WO-A-96/31615) and 6.7 g sodium bicarbonate in 40 ml methylene chloride and 10 ml water. CO₂ gas escaped, while the pH remained at 5. After stirring for one hour, according to gas-liquid chromatography (GLC) the starting material had been fully converted. The bromine excess was neutralized with solid Na₂S₂O₃. After phase separation the water phase was extracted with 2 times 100 ml ethyl acetate. The combined organic phases were dried over Na₂SO₄ and filtered. After rotavap evaporation 5.5 g yellow oil was obtained (82% yield of the compound of formula (2) with X = Cl relative to compound I).

¹H NMR (200 MHz, CDCl₃):

δ 1.8-2.1 (m, 2H); 2.6-2.7 (m, 2H); 3.5-3.8 (m, 2H (CH₂Cl)); 4.4 (m, 1H); 4.9 (m, 1H).

Example II

Preparation of (4R,6S)-4-hydroxy-6-chloromethyl-tetrahydropyran-2-one

(Compound II; covered by formula 2)

[0027] To a solution of 75g (450 mmole) compound I in 390 ml water was added 114g (715 mmole) of bromine at 15-25°C in 3 hours. The pH of the reaction mixture was maintained at 5-6 via the simultaneous addition of sodium carbonate (88g total amount). The excess of bromine was neutralized with sodium bisulfite. The product was extracted from the water phase with ethyl acetate (counter-current extraction).

[0028] The product was crystallized from ethyl acetate/ heptane (125g / 62g). After cooling to 0°C, the crystals were filtered, washed with 50 ml of heptane / ethyl acetate (w:w = 9:1) and dried, yielding 49.2g (67% relative to compound I). of compound II as colourless needles (m.p. 73-74°C).

Example III

Preparation of (4R-cis)-6-(chloromethyl)-2,2-dimethyl-1,3-dioxane-4-yl acetic acid methyl ester (compound III)

[0029] 5.5 g of compound II as obtained in example I was added to 20 ml commercial dimethoxy propane and 100 mg p-toluene sulphonic acid monohydrate at room temperature. After stirring for one hour at room temperature GLC analysis showed that full conversion had taken place and a clear solution had been formed. After addition of 500 mg NaHCO₃ stirring took place for 30 minutes at room temperature. After filtration and rotavap evaporation 7.1 g compound III was obtained as a light-yellow oil (91% relative to compound II).

¹H NMR (200 MHz, CDCl₃):

δ 1.25 (dt, 1H); 1.40 (s, 3H); 1.47 (s, 3H);
1.79 (dt, 1H); 2.42 (dd, 1H); 2.58 (dd, 1H);
3.40 (dd, 1H); 3.52 (dd, 1H); 3.70 (s, 3H);
4.1 (m, 1H); 4.35 (m, 1H).

Example IV**Preparation of (4R-cis)-6-(chloromethyl)-2,2-dimethyl-1,3-dioxane-4-yl acetic acid methyl ester (compound III)**

5 [0030] To a solution of 49.2g (300 mmole) of compound II in 100 ml of toluene was added 47g (450 mmole) dimethoxy propane and 850 mg p-toluene sulphonic acid monohydrate (4.5 mmole).

After stirring for one hour at room temperature, GLC analysis showed complete conversion of compound II.

The toluene phase was washed with 50 ml of a 0.2N NaOH solution in water. After evaporation 67g of compound III was obtained as a light-yellow oil (94% relative to compound II).

Example V**(4R-cis)-(6-chloromethyl)-2,2-dimethyl-1,3-dioxane-4-yl-acetic acid, sodium salt (compound IV)**

15 [0031] 55 g (233 mmol) of compound III was added to 200 ml water. At room temperature 20 g of a 50% NaOH solution in water was added dropwise in 2 hours at pH = 12. The hydrolysis was monitored using GLC. After 20 g the pH remained constant. Concentrated hydrochloric acid was used to lower the pH to 10. The water phase was washed with 100 ml ethyl acetate and evaporated using a rotavap. The oil formed was dried by stripping with absolute ethanol and toluene. The solid was stirred into 200 ml acetone, filtered and washed with cold acetone. Yield after vacuum drying: 45.6 g = 80% Na salt relative to compound III.

¹H NMR (200 MHz, CDCl₃/CD₃OD):

δ 1.21 (dt, 1H); 1.36 (s, 3H); 1.49 (s, 3H);

1.79 (dt, 1H); 2.25 (dd, 1H); 2.45 (dd, 1H); 3.46

(m, 2H); 4.11 (m, 1H); 4.36 (m, 1H).

Example VI**(4R-cis)-(6-chloromethyl)-2,2-dimethyl-1,3-dioxane-4-yl-acetic acid, sodium salt (compound IV)**

30 [0032] Starting from 49.2g compound I, a solution of compound III in toluene was prepared as described in example IV. 5g methanol and 25 ml of water were added. At room temperature 25g of a 50% solution of NaOH in water was added dropwise in 1 hour.

After stirring for 4 hours at room temperature, GLC analysis indicated complete hydrolysis.

The excess of base was neutralized to pH 8.5-9.5 with 33% HCl solution in water.

35 The waterphase was separated and dried via azeotropic distillation using 470 ml of toluene, yielding 65g compound IV as a 16 w/w% suspension in toluene with KF < 0.1%.

The suspension can be used for the synthesis of compound V.

Example VII**(4R-cis)-(6-chloromethyl)-2,2 dimethyl-1,3-dioxane-4-yl-acetic acid, t-butyl ester (compound V)**

40 [0033] 45.5 g IV, sodium salt (186 mmol) was added to a solution of 159 g ditert. butyl dicarbonate in 1400 ml dry tert. butanol. After addition of 6.8 g dimethylamino pyridine stirring took place for 16 hours at 40°C. The reaction mixture was poured out into 1500 ml ethyl acetate and 1000 ml saturated ammonium chloride. The water phase was re-extracted with 1500 ml ethyl acetate. The combined organic phases were washed with 600 ml saturated NaCl solution. The organic layer was dried over Na₂SO₄, filtered and then evaporated under vacuum, yielding 51.9 g yellow oil (100% relative to compound IV).

¹H NMR (200 MHz, CDCl₃):

δ 1.15-1.33 (m, 1H); 1.40 (s, 3H); 1.45 (s, 3H);

1.47 (s, 9H) 1.77 (dt, 1H); 2.33 (dd, 1H); 2.46

(dd, 1H); 3.40 (dd, 1H); 3.49 (dd, 1H) 4.08 (m, 1H); 4.28 (m, 1H).

Example VIII**(4R-cis)-6-[(acetoxymethyl)-2,2-dimethyl-1,3-dioxane-4-yl-acetic acid, t-butyl ester (compound VI)**

55 [0034] Starting from 33 g of compound V obtained according to example VII, in 16 hours 29 g of compound VI was

obtained at 100°C according to US-A-5457227 (using 40 g tetra-n-butyl ammonium acetate and in 200 ml DMF), as a solid after crystallization from 75 ml heptane.

¹H NMR (200 MHz, CDCl₃):

δ 1.1-1.3 (dt, 1H); 1.39 (s, 3H); 1.45 (s, 9H);

1.47 (s, 3H); 1.57 (dt, 1H); 2.08 (s, 3H); 2.32

(dd, 1H); 2.46 (dd, 1H); 4.0-4.2 (m, 3H); 4.3 (m, 1H).

Example IX

(4R-cis)-6-[hydroxymethyl]-2,2-dimethyl-1,3-dioxane-4-yl-acetic acid, t-butyl ester (compound VII)


[0035] Starting from 29 g of compound VI according to example V, 25.0 g compound VII was obtained as a light-yellow oil with e.e. = 100%, d.e. = 99.9% (according to GLC) according to US-A-5457227 (use being made of 6.9 g potassium carbonate in 300 ml methanol).

¹H NMR (200 MHz, CDCl₃):



Spectrum was in line with literature (Synthesis 1014, 1995).

Claims

- Compound according to formula (2), wherein X is a halogen, a tosylate group, a mesylate group, an acyloxy group, an aryloxy-substituted benzene sulphonyl group, or a nitro-substituted benzene sulphonyl group, and whereby the compound is in the (4R, 6S) form.



- 2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivative of formula 1 or 3, wherein X represents a leaving group; R₁, R₂ and R₃ each independently represent an alkyl group with 1-3 carbon atoms and Y represents an alkaline (earth) metal or a substituted or unsubstituted ammonium group.



- 2-(6-Substituted-1,3-dioxane-4-yl)acetic acid derivative according to claim 2, where R₁, R₂ and, if present, R₃ = CH₃ and Y = Na, Ca or a tetraalkyl ammonium compound.

4. Compound according to any one of claims 1-3, where X stands for Cl.

5

10

15

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 06 01 0837

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
E	WO 01/72706 A (BIOCON INDIA LIMITED; SAMBASIVAN, GANESH; SRIDHARAN, MADHAVAN; PADUDEV) 4 October 2001 (2001-10-04) example 1.7; compound VII -----	2,3	INV. C07D319/06
X	WO 97/19917 A (L'OREAL; SOLLADIE, GUY; BAUDER, CLAUDE) 5 June 1997 (1997-06-05) annex 2, compounds 9, 11 -----	2,3	
X	WO 93/08823 A (TANABE SEIYAKU CO., LTD; MCKENZIE, THOMAS, C) 13 May 1993 (1993-05-13) * page 41, lines 1-17 * -----	2	
X	MARKUS MENGES, REINHARD BRÜCKNER: "Oxidative Degradation of gamma-Butyrolactons into 1,3-Diols via a Criegee Rearrangement of Peroxosulfonates. An Enantioselective Synthesis of Compactin Lactone and its Diastereomer" SYNLETT, vol. 1993, no. 12, 1993, pages 901-905, XP002387176 compound 18 -----	2,3	TECHNICAL FIELDS SEARCHED (IPC) C07D
X	LIMING SHAO, HIROYUKI KAWANO, MASAHIKO SABURI, YASUZO UCHIDA: "Asymmetric Hydrogenation of 3,5-Dioxoesters Catalyzed by Ru-binap Complex: A Short Step Asymmetric Synthesis of 6-Substituted 5,6-dihydro-2-pyrones" TETRAHEDRON, vol. 49, no. 10, 1993, pages 1997-2010, XP002387177 compound 9c ----- -/--	2,3	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 26 June 2006	Examiner Rudolf, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.02 (P04CO1)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 06 01 0837

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	KANEKO CHIKARA ET AL: "PREPARATION OF OPTICALLY ACTIVE 5,6-EPOXYHEXANOIC ACID ESTERS AS MATERIALS FOR PHYSIOLOGICALLY ACTIVE SUBSTANCES" CHEMICAL ABSTRACTS + INDEXES, AMERICAN CHEMICAL SOCIETY, COLUMBUS, US, vol. 118, no. 11, 1993, page 832, XP002178273 ISSN: 0009-2258 compound VI	1,4	
A	SAKAKI J-I ET AL: "LIPASE CATALYSED ASYMETRIC SYNTHESIS OF 6-(3-CHLORO-2-HYDROXYPROPYL)-1,3-DIOXIN-4-ONES AND THEIR CONVERSION TO CHIRAL 5,6-EPOXAHEXANOATES" TETRAHEDRON: ASYMMETRY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 2, no. 5, 1991, pages 343-346, XP002178271 ISSN: 0957-4166 compound 8	1,4	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 26 June 2006	Examiner Rudolf, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

 2
EPO FORM 1503 03/82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 06 01 0837

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

26-06-2006

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0172706 A	04-10-2001	AU 5424900 A	08-10-2001
WO 9719917 A	05-06-1997	AT 199709 T	15-03-2001
		DE 69612086 D1	19-04-2001
		DE 69612086 T2	21-06-2001
		EP 0805800 A1	12-11-1997
		ES 2157466 T3	16-08-2001
		FR 2741620 A1	30-05-1997
		JP 10504845 T	12-05-1998
		JP 3119663 B2	25-12-2000
WO 9308823 A	13-05-1993	NONE	

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 3325466 A [0021]
- US 5594153 A [0022]
- EP 1024139 A [0022]
- WO 9631615 A [0024] [0026]
- US 5457227 A [0034] [0035]

Non-patent literature cited in the description

- *J. Org. Chem.*, 1970, vol. 35, 2429 [0021]
- *Org. Synth.*, 1971, vol. 51, 96 [0021]
- *Z. Chem.*, 1972, vol. 12 (7), 264 [0021]
- *Tetr. Let.*, 1993, vol. 34 (46), 7409 [0021]
- *Synth. Comm.*, 1979, vol. 9, 542 [0021]
- *Tetr. Let.*, 1998, vol. 39, 1557 [0021]
- *Bull. Chem. Soc. Japan*, 1979, vol. 52 (7), 1989 [0021]
- *Synthesis*, 1994, vol. 1063 [0021]
- *Org Process R&D*, 1999, vol. 3, 172 [0021]
- *Heterocycles*, 1990, vol. 31 (11), 2055 [0021]
- **M. WATANABE**. *Drugs of the future*, 1999, vol. 24 (5), 511-513 [0023]
- *Bioorg. & Med. Chem.*, 1997, vol. 5 (2), 437-444 [0023]

HKP0720331

名称

制备 2-(6-取代的-1,3-二噁烷-4-基)乙酸衍生物的方法

摘要

本发明涉及在酸催化剂存在下，借助于缩醛化试剂，从 4-羟基-6-X-取代的-甲基-四氢吡喃-4-酮化合物，其中 X 代表离去基团，制备式 1 的 2-(6-取代的-1,3-二噁烷-4-基)乙酸衍生物，其中 X 如上定义， R_1 、 R_2 和 R_3 各自独立地代表具有 1-3 个碳原子的烷基。

本发明还涉及式 1 的新化合物，以及通过将式 1 中的 OR_3 基团替换为 OY 基团而由其制备的盐和酸，其中 X、 R_1 和 R_2 具有如上的定义，Y 代表碱（土）金属，或取代或者未取代的铵，或代表氢，并且涉及式 2 的新化合物。

所关心的产物在转变为 2-(6-羟甲基-1,3-二噁烷-4-基)乙酸的叔丁酯后，成为制备他汀中的重要中间产物。